Cyprotex Extends Time Dependent Inhibition Service to Include the Cytochrome P450 Isoform, CYP2B6
Cyprotex, a preclinical ADME Tox services company, has extended its time-dependent inhibition service to include the cytochrome P450 (CYP450) isoform, CYP2B6.
Cyprotex, a preclinical ADME Tox services company, has extended its time-dependent inhibition service to include the cytochrome P450 (CYP450) isoform, CYP2B6.
Inhibition of the various CYP450 isoforms, including CYP2B6, is one of the main causes of drug-drug interactions. Drug-drug interactions can cause otherwise safe medicines to accumulate in the body resulting in toxicity.
A US FDA update paper by Huang et al., 2008 (J Clin Pharmacol 48; 662-670) has highlighted the importance of CYP2B6 in clinical interactions and recommends that CYP2B6 should be investigated in vitro when assessing whether enzyme inhibition or induction has the potential to produce a drug interaction.
CYP450 inhibition can produce either reversible or irreversible drug-drug interactions. Time-dependent inhibition assays identify compounds which have the potential to form an irreversible drug-drug interaction. These types of drug-drug interactions, although less common,
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance